Table 2.
The effects of different clinicopathological factors on MYL9 gene expression and clinical prognosis of ovarian cancer were determined by Kaplan–Meier plotter
| Clinicopathological characteristics | Overall survival (n = 1656) | Progression‐free survival (n = 1435) | ||||
|---|---|---|---|---|---|---|
| N | Hazard ratio | p value | N | Hazard ratio | p value | |
| Stage | ||||||
| I | 74 | 2.54 (0.68−9.45) | .15 | 96 | 3.91 (1.36−11.24) | .006 |
| I + II | 135 | 1.99 (0.75−5.29) | .16 | 163 | 1.84 (1.01−3.33) | .042 |
| II | 61 | 3.38 (0.73−15.57) | .1 | 67 | 1.46 (0.65−3.25) | .36 |
| II + III | 1105 | 1.29 (1.09−1.53) | .003 | 986 | 1.49 (1.28−1.73) | 1.7E−07 |
| II + III + IV | 1281 | 1.34 (1.12−1.59) | .001 | 1148 | 1.54 (1.34−1.77) | 7.8E−10 |
| III | 1044 | 1.27 (1.07−1.51) | .006 | 919 | 1.49 (1.28−1.74) | 3.7E−07 |
| III + IV | 1220 | 1.26 (1.07−1.47) | .004 | 1081 | 1.54 (1.34−1.77) | 2E−09 |
| IV | 176 | 2.81 (1−7.86) | .042 | 162 | 1.88 (1.29−2.74) | .001 |
| Histology | ||||||
| Endometrioid | 37 | 7.65 (1.26−46.43) | .009 | 51 | 3.75 (1.45−9.7) | .004 |
| Serous | 1207 | 1.29 (1.1−1.51) | .001 | 1104 | 1.61 (1.39−1.86) | 9.3E−11 |
| TP53 mutation | ||||||
| Mutated | 509 | 1.35 (1.03−1.76) | .026 | 483 | 1.43 (1.14−1.78) | .002 |
| Wild type | 94 | 1.61 (0.94−2.77) | .08 | 84 | 1.75 (1.02−3.02) | .04 |
| Debulk | ||||||
| Optimal | 801 | 1.52 (1.23−1.88) | 9.7e−05 | 696 | 1.49 (1.23−1.8) | 4.3E−05 |
| Suboptimal | 536 | 1.21 (0.96−1.51) | .099 | 459 | 1.25 (1−1.57) | .046 |
Abbreviation: MYL9, myosin light chain 9.